Dr. Carlisle has over 30 years’ experience in healthcare and biomedical research and holds a BA in Biology from Fisk University, a Doctorate in Biochemistry & Molecular Biology from Howard University, and received post-doctoral training at the NIH where he helped lead the NCI Cancer Genome Anatomy Project and identified molecular therapeutic targets in Parkinson’s Disease at the NINDS. After the NIH, he went on to lead research efforts at several top academic medical centers, including: Fox Chase Cancer Center, Children’s Hospital of Philadelphia, and Inova Fairfax Hospital, where he helped establish the Inova Neuroscience Research Institute and Inova-George Mason University Neuroscience Translational Research (INTR) Laboratory, and served as Founder and Director of the Laboratory of Neuro-Oncology.
Dr. Carlisle later went on to Northrop Grumman Health where he led the development of their Precision Oncology Analytics Platform, and founded and managed a partnership with UCSF to design decision support user interfaces to support the I-SPY Clinical Trial, all while serving as Chief Scientific Officer and Program Manager for their Precision Healthcare Business Unit. In addition to his professional career, Dr. Carlisle has a deep history of advocacy and community outreach having worked with former longstanding community leader Roscoe "Mr. Chic" Bradley and his Colonial Park Community Services, Inc. to provide social programs and services for at-risk communities in Harlem, NY.
Dr. Carlisle has broad experience building and leading public-private partnerships with stakeholders such as PricewaterhouseCoopers (PwC), Hospital Corporation of America (HCA), and the State of New York, where he has focused on creating programs and research infrastructure aimed at addressing health disparities and improving patient outcomes through bringing advanced precision medicine-based care to underserved populations in various communities.
Dr. Carlisle now continues this legacy as the Founder, Chairman, and CEO of the National Alliance against Disparities in Patient Health (NADPH). In addition to his work at NADPH, Dr. Carlisle consults organizations on their scientific and health business development strategy and provides thought leadership and community service at a National level in science, patient advocacy, and health policy through his representation on Boards for organizations like the Leukemia & Lymphoma Society, Personalized Medicine Coalition, and the EP3 Foundation.